Mnogotselevaya terapiya sindroma razdrazhennogo kishechnika: sovremennyy vzglyad na reshenie problemy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the analysis of the evidence base of treatment of irritable bowel syndrome (IBS). A large number of randomized, placebo-controlled trials systematized in several meta-analyzes show the effectiveness of monotherapy treatment regimens. Because IBS has a multifactorial pathogenesis with respect to triggers and pathogenetical ways, we suppose that for the majority of IBS patients need for combined and even personalized approaches to the treatment affecting several components of pathogenesis. This viewpoint is confirmed by international publications in recent years. The choice of pharmacotherapy of IBS in each case is a difficult decision, because it is determined by the form of the syndrome, the availability of a proven drug in the internal market, indications and the possibility of long-term use, high safety, and effectiveness according to the evidence-based criteria. In clinical practice, the use of traditional pharmacotherapy supplemented with specific herbal medicine or other types of complementary and alternative therapy can provide a better treatment outcome and significantly affect the quality of life of these patients. The potentials for the application of phytopreparation Iberogast®, which is a mixture of herbal extracts of nine plants, is considered in IBS.

Full Text

Restricted Access

References

  1. Drossman D.A. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology. 2006;130(5):1377-90.
  2. Canavan C., West J., Card T. The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 2014;6:71-80.
  3. Drossman D.A., Morris C.B., Schneck S., Hu Y.J., Norton N.J., NortonW.F, Weinland S.R.,Dalton C., Leserman J., Bangdiwala S.I. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J. Clin. Gastroenterol. 2009;43:541-50.
  4. Inadomi J.M., Fennerty M.B., Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2003;18:671-82.
  5. McFarland L.V. State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. World J. Gastroenterol. 2008;14:2625-29.
  6. Маев И.В., Кучерявый Ю.А., Черемушкин С.В. Эволюция представлений о синдроме раздраженного кишечника. Методическое пособие для врачей. М., 2013.
  7. Katiraei P., Bultron G. Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome. World J. Gastroenterol. 2011;17:2791-2800.
  8. Grundmann O., Yoon S.L. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J. Gastroenterol. Hepatol. 2010;25:691-99.
  9. Coëffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Antonietti M., Savoye G., Bоle-Feysot C., Dеchelotte P., et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am. J. Gastroenterol. 2010;105:1181-88.
  10. Scully P., McKernan D.P., Keohane J., Groeger D., Shanahan F., Dinan T.G., Quigley E.M. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am. J. Gastroenterol. 2010;105:2235-43.
  11. Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Черемушкина Н.В. Спазмолитическая терапия синдрома раздраженного кишечника, основанная на принципе доказательной медицины. Фарматека. 2012;10(243):16-22.
  12. Brandt L.J., Chey W.D. Foxx-Orenstein A.E., Schiller L.R., Schoenfeld P.S., Spiegel B.M., Talley N.J., Quigley E.M. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol. 2009;104(1):1-35.
  13. Ruepert T., Quartero А., de Wit N., van der Heijden G.J., Rubin G., MurisJ.W. Bulking agents, antispasmodics and antidepressants for the treatment of irritаblе bowel syndrome. Cochrane Database Syst. Rev. 2011;8:CD003460.
  14. Chang, L., Lembo, A., Sultan S. American Gastroenterological Association technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147:1149-72.
  15. Grundmann О., Yoon S.L. Complementary and alternative medicines in irritable bowel syndrome: An integrative view. World. J. Gastroenterol. 2014;20(2):346-62.
  16. Rösch W., Vinson B., Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z. Gastroenterol. 2002;40:401-08.
  17. von Arnim U., Peitz U., Vinson B., Gundermann K.J., Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am. J. Gastroenterol. 2007; 102:1268-75.
  18. Simmen U., Kelber O., Okpanyi S.N., Jaeggi R., Bueter B., Weiser D. Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine. 2006; 13(Suppl 5):51-5.
  19. Madisch A., Holtmann G., Plein K., Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a doubleblind, randomized, placebo-controlled, multicentre trial. Aliment. Pharmacol. Ther. 2004; 19:271-79.
  20. Ottillinger B., Storr M., Malfertheiner P., Allescher H.D. STW 5 (Iberogast®) - a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med. Wochenschr. 2013;163:65-72.
  21. Layer P., Andresen V., Pehl C. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM). Z. Gastroenterol. 2011;49: 237-93.
  22. Malfertheiner P., Holtmann G., Peitz U. Guidelines of the German society of metabolic and digestive diseases for the therapy of dyspepsia. Z. Gastroenterol. 2001;39(11): 937-56.
  23. World Gastroenterology Organization. Global Guideline. Irritable bowel syndrome: a global perspective. 2009.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies